CLINICAL TRIALS PROFILE FOR AMOXAPINE
✉ Email this page to a colleague
All Clinical Trials for amoxapine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000272 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| NCT00000272 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | New York State Psychiatric Institute | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| NCT00000272 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | Research Foundation for Mental Hygiene, Inc. | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| NCT00000317 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| NCT00000317 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | Research Foundation for Mental Hygiene, Inc. | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| NCT00000317 ↗ | Early Phase II Trials for Cocaine Medication Development - 1 | Completed | New York State Psychiatric Institute | Phase 2 | 1996-08-01 | The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This |
| NCT00444028 ↗ | Staccato Loxapine Single Dose PK | Completed | Alexza Pharmaceuticals, Inc. | Phase 1 | 2005-09-01 | The objective of this study was to assess the safety, tolerability and pharmacokinetics of a single inhaled dose of (administered in 1 or 2 puffs) Staccato Loxapine in healthy volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amoxapine
Condition Name
Clinical Trial Locations for amoxapine
Trials by Country
Clinical Trial Progress for amoxapine
Clinical Trial Phase
Clinical Trial Sponsors for amoxapine
Sponsor Name
